Home › Trials › NCT07010263

AK112 consolidation therapy for limited-stage small cell lung cancer after concurrent chemoradiation

A Multicenter, Randomized, Double-blind, Phase III Clinical Study of Comparing the Efficacy and Safety of AK112 (PD-1/VEGF Bispecific Antibody) Versus Placebo as Consolidation Treatment for Patients With Limited Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Phase 3 Interventional Akeso · NCT07010263

This trial will test whether the experimental antibody AK112 (ivonescimab) given after successful concurrent chemoradiation can help prevent recurrence in adults with limited-stage small cell lung cancer.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment560 (estimated)
Ages18 Years and up
SexAll
SponsorAkeso Industry-sponsored
Drugs / interventionsprednisone
Locations53 sites (Beijing, Beijing Municipality and 52 other locations)
Trial IDNCT07010263 on ClinicalTrials.gov

What this trial studies

This randomized, double-blind phase III trial will assign patients who have not progressed after concurrent chemoradiation to receive either AK112 (ivonescimab) or placebo as consolidation therapy. Participants will be treated and followed at participating centers for safety and signs of disease recurrence. The study will compare time to progression and safety outcomes between the AK112 and placebo groups. The goal is to determine whether adding AK112 after chemoradiation can extend the period without cancer progression while maintaining an acceptable safety profile.

Who should consider this trial

Good fit: Adults (≥18 years) with histologically confirmed limited-stage small cell lung cancer who completed concurrent chemoradiotherapy without progression, have ECOG 0–1, adequate organ function, and agree to required contraception and testing are ideal candidates.

Not a fit: Patients who have already progressed after chemoradiation, have metastatic disease, poor performance status (ECOG >1), or cannot comply with study visits are unlikely to benefit from this trial.

Why it matters

Potential benefit: If successful, AK112 could prolong the time without disease progression and possibly improve survival for patients with limited-stage small cell lung cancer after chemoradiation.

How similar studies have performed: Immune checkpoint inhibitors have shown benefit in extensive-stage SCLC, but using consolidation immunotherapy specifically in limited-stage SCLC is less tested and clinical data are currently limited.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

Inclusion Criteria:

1. The subjects voluntarily participated in the study with full informed consent and signed written informed consent form.
2. Aged ≥18 years on day fo signing the informed consent.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
4. Life expectancy ≥ 3 months
5. Histologically or cytologically confirmed small cell lung cancer.
6. Documented limited-stage SCLC (Stage I-III SCLC \[T any, N any, M0\] according to the American Joint Committee on Cancer Staging Manual \[AJCC Cancer Staging Manual, 8th Edition\] or the Veterans Administration Lung Study Group (VALG) stage.
7. Have Received concurrent chemoradiotherapy regimen as defined in protocol and have not progressed following concurrent chemoradiotherapy.
8. Adequate organ function.
9. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and agree to take effective contraception measures during the study drug administration and within 120 days after the last dose.

Exclusion Criteria:

1. Histologically or cytological confirmed the presence of mixed small cell lung cancer or non-small cell lung cancer components.
2. Toxicities from previous anti-tumor treatments have not resolved to grade 0 or 1 based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0), or to the levels specified in inclusion/exclusion criteria, except for alopecia.
3. Symptoms or signs of primary disease deterioration that the investigator judges clinically unacceptable, such as cachexia.
4. Presence of pleural effusion, pericardial effusion, or ascites, which was clinically symptomatic or requiring frequent drainage.
5. History of active malignant tumors within the previous 5 years.
6. Received major surgery within 28 days prior to the first dose of study drug, or expected to undergo major surgery during the study period within 28 days after the first dose of study drug.
7. Uncontrolled comorbidities, including but not limited to decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, severe active peptic ulcer disease or gastritis, and other related diseases..
8. Have serious neurological or mental illnesses, including dementia and epileptic seizures.
9. Pregnant or lactating women.
10. Have cardiovascular or cerebrovascular diseases or risk factors.
11. Prior treatments with systemic non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, etc.) within 2 weeks before the first administration of the study drugs. Prior treatment with Chinese herbal medicine or traditional Chinese patent medicines with anti-tumor indications within 1 weeks before the first administration of the study drugs.
12. Prior treatments targeting immune mechanisms, including, but not limited to, immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy.
13. Prior treatments with anti-angiogenic therapy.
14. Subjects requiring systemic treatment with corticosteroids (\>10mg/day prednisone or equivalent dose) or other immunosuppressive drugs within 14 days prior to the first dose of study drug.
15. Known history of severe hypersensitivity reactions to other monoclonal antibodies or with a known history of allergy or hypersensitivity reactions to any of study drugs or their components.
16. Active autoimmune diseases that require systemic treatment within 2 years prior to the study, or autoimmune diseases that the investigator judges to be potentially recurrent or require planned treatment.
17. Known interstitial lung disease or non infectious pneumonia, which currently has symptoms or requires systemic corticosteroid treatment in the past,or investigator juges may affect the toxicity assessment or management related to the study treatment.
18. Known severe infection within 4 weeks prior to the first dose of study drug. Known active tuberculosis. Known active syphilis infection. Known history of immunodeficiency or positive HIV test results.
19. .Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
20. Active hepatitis B or active hepatitis C.
21. Received a live vaccine within 30 days prior to the first dose of study drug, or planning to receive a live vaccine during the study period.

Where this trial is running

Beijing, Beijing Municipality and 52 other locations

+3 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Small Cell Lung CancerAK112Ivonescimab
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.